PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Mecasermin→

Mecasermin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
68562-41-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Recombinant human insulin-like growth factor 1 (IGF-1)growth factor replacement biologic
Mechanism of action
Binds and activates the IGF-1 receptor, stimulating cellular growth, differentiation and metabolism. It provides replacement of deficient IGF-1 activity in severe primary IGF-1 deficiency.
Indications / reported uses
  • Treatment of growth failure in paediatric patients aged 2 years and older with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralising antibodies to growth hormone; not a substitute for growth hormone in other causes of short stature

Sources: US DailyMed — INCRELEX (mecasermin) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Mecasermin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mecasermin Permitted Daily Exposure (PDE) report (the Mecasermin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mecasermin Occupational Exposure Limit (OEL) report (the Mecasermin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.